Report cover image

Global Venous Thromboembolism Therapeutics Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 193 Pages
SKU # APRC20552772

Description

Summary

According to APO Research, The global Venous Thromboembolism Therapeutics Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Venous Thromboembolism Therapeutics Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Venous Thromboembolism Therapeutics Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Venous Thromboembolism Therapeutics Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Venous Thromboembolism Therapeutics Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Venous Thromboembolism Therapeutics Drugs include Sanofi, Johnson & Johnson, Bayer, Gamma Therapeutics, eXIthera Pharmaceuticals, Daiichi Sankyo, Boehringer Ingelheim, BMS and BioInvent, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Venous Thromboembolism Therapeutics Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Venous Thromboembolism Therapeutics Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Venous Thromboembolism Therapeutics Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Venous Thromboembolism Therapeutics Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Venous Thromboembolism Therapeutics Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Venous Thromboembolism Therapeutics Drugs sales, projected growth trends, production technology, application and end-user industry.

Venous Thromboembolism Therapeutics Drugs Segment by Company

Sanofi
Johnson & Johnson
Bayer
Gamma Therapeutics
eXIthera Pharmaceuticals
Daiichi Sankyo
Boehringer Ingelheim
BMS
BioInvent
Aspen Pharma
Armetheon
Altor Bioscience
Venous Thromboembolism Therapeutics Drugs Segment by Type

Warfarin
Heparin
Dabigatran
Rivaroxaban
Edaxaban
Apixaban
Venous Thromboembolism Therapeutics Drugs Segment by Application

Hospital
Clinic
Venous Thromboembolism Therapeutics Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Venous Thromboembolism Therapeutics Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Venous Thromboembolism Therapeutics Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Venous Thromboembolism Therapeutics Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Venous Thromboembolism Therapeutics Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Venous Thromboembolism Therapeutics Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Venous Thromboembolism Therapeutics Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Venous Thromboembolism Therapeutics Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Venous Thromboembolism Therapeutics Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global Venous Thromboembolism Therapeutics Drugs Market Size Estimates and Forecasts (2020-2031)
1.4 Global Venous Thromboembolism Therapeutics Drugs Sales Estimates and Forecasts (2020-2031)
1.5 Global Venous Thromboembolism Therapeutics Drugs Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Venous Thromboembolism Therapeutics Drugs Market Dynamics
2.1 Venous Thromboembolism Therapeutics Drugs Industry Trends
2.2 Venous Thromboembolism Therapeutics Drugs Industry Drivers
2.3 Venous Thromboembolism Therapeutics Drugs Industry Opportunities and Challenges
2.4 Venous Thromboembolism Therapeutics Drugs Industry Restraints
3 Venous Thromboembolism Therapeutics Drugs Market by Manufacturers
3.1 Global Venous Thromboembolism Therapeutics Drugs Revenue by Manufacturers (2020-2025)
3.2 Global Venous Thromboembolism Therapeutics Drugs Sales by Manufacturers (2020-2025)
3.3 Global Venous Thromboembolism Therapeutics Drugs Average Sales Price by Manufacturers (2020-2025)
3.4 Global Venous Thromboembolism Therapeutics Drugs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Venous Thromboembolism Therapeutics Drugs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Venous Thromboembolism Therapeutics Drugs Manufacturers, Product Type & Application
3.7 Global Venous Thromboembolism Therapeutics Drugs Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Venous Thromboembolism Therapeutics Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Venous Thromboembolism Therapeutics Drugs Players Market Share by Revenue in 2024
3.8.3 2024 Venous Thromboembolism Therapeutics Drugs Tier 1, Tier 2, and Tier 3
4 Venous Thromboembolism Therapeutics Drugs Market by Type
4.1 Venous Thromboembolism Therapeutics Drugs Type Introduction
4.1.1 Warfarin
4.1.2 Heparin
4.1.3 Dabigatran
4.1.4 Rivaroxaban
4.1.5 Edaxaban
4.1.6 Apixaban
4.2 Global Venous Thromboembolism Therapeutics Drugs Sales by Type
4.2.1 Global Venous Thromboembolism Therapeutics Drugs Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Venous Thromboembolism Therapeutics Drugs Sales by Type (2020-2031)
4.2.3 Global Venous Thromboembolism Therapeutics Drugs Sales Market Share by Type (2020-2031)
4.3 Global Venous Thromboembolism Therapeutics Drugs Revenue by Type
4.3.1 Global Venous Thromboembolism Therapeutics Drugs Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Venous Thromboembolism Therapeutics Drugs Revenue by Type (2020-2031)
4.3.3 Global Venous Thromboembolism Therapeutics Drugs Revenue Market Share by Type (2020-2031)
5 Venous Thromboembolism Therapeutics Drugs Market by Application
5.1 Venous Thromboembolism Therapeutics Drugs Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.2 Global Venous Thromboembolism Therapeutics Drugs Sales by Application
5.2.1 Global Venous Thromboembolism Therapeutics Drugs Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Venous Thromboembolism Therapeutics Drugs Sales by Application (2020-2031)
5.2.3 Global Venous Thromboembolism Therapeutics Drugs Sales Market Share by Application (2020-2031)
5.3 Global Venous Thromboembolism Therapeutics Drugs Revenue by Application
5.3.1 Global Venous Thromboembolism Therapeutics Drugs Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Venous Thromboembolism Therapeutics Drugs Revenue by Application (2020-2031)
5.3.3 Global Venous Thromboembolism Therapeutics Drugs Revenue Market Share by Application (2020-2031)
6 Global Venous Thromboembolism Therapeutics Drugs Sales by Region
6.1 Global Venous Thromboembolism Therapeutics Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Venous Thromboembolism Therapeutics Drugs Sales by Region (2020-2031)
6.2.1 Global Venous Thromboembolism Therapeutics Drugs Sales by Region (2020-2025)
6.2.2 Global Venous Thromboembolism Therapeutics Drugs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Venous Thromboembolism Therapeutics Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Venous Thromboembolism Therapeutics Drugs Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Venous Thromboembolism Therapeutics Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Venous Thromboembolism Therapeutics Drugs Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Venous Thromboembolism Therapeutics Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Venous Thromboembolism Therapeutics Drugs Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Venous Thromboembolism Therapeutics Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Venous Thromboembolism Therapeutics Drugs Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Venous Thromboembolism Therapeutics Drugs Revenue by Region
7.1 Global Venous Thromboembolism Therapeutics Drugs Revenue by Region
7.1.1 Global Venous Thromboembolism Therapeutics Drugs Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Venous Thromboembolism Therapeutics Drugs Revenue by Region (2020-2025)
7.1.3 Global Venous Thromboembolism Therapeutics Drugs Revenue by Region (2026-2031)
7.1.4 Global Venous Thromboembolism Therapeutics Drugs Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Venous Thromboembolism Therapeutics Drugs Revenue (2020-2031)
7.2.2 North America Venous Thromboembolism Therapeutics Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Venous Thromboembolism Therapeutics Drugs Revenue (2020-2031)
7.3.2 Europe Venous Thromboembolism Therapeutics Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Venous Thromboembolism Therapeutics Drugs Revenue (2020-2031)
7.4.2 Asia-Pacific Venous Thromboembolism Therapeutics Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Venous Thromboembolism Therapeutics Drugs Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Venous Thromboembolism Therapeutics Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Sanofi
8.1.1 Sanofi Comapny Information
8.1.2 Sanofi Business Overview
8.1.3 Sanofi Venous Thromboembolism Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Sanofi Venous Thromboembolism Therapeutics Drugs Product Portfolio
8.1.5 Sanofi Recent Developments
8.2 Johnson & Johnson
8.2.1 Johnson & Johnson Comapny Information
8.2.2 Johnson & Johnson Business Overview
8.2.3 Johnson & Johnson Venous Thromboembolism Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Johnson & Johnson Venous Thromboembolism Therapeutics Drugs Product Portfolio
8.2.5 Johnson & Johnson Recent Developments
8.3 Bayer
8.3.1 Bayer Comapny Information
8.3.2 Bayer Business Overview
8.3.3 Bayer Venous Thromboembolism Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Bayer Venous Thromboembolism Therapeutics Drugs Product Portfolio
8.3.5 Bayer Recent Developments
8.4 Gamma Therapeutics
8.4.1 Gamma Therapeutics Comapny Information
8.4.2 Gamma Therapeutics Business Overview
8.4.3 Gamma Therapeutics Venous Thromboembolism Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Gamma Therapeutics Venous Thromboembolism Therapeutics Drugs Product Portfolio
8.4.5 Gamma Therapeutics Recent Developments
8.5 eXIthera Pharmaceuticals
8.5.1 eXIthera Pharmaceuticals Comapny Information
8.5.2 eXIthera Pharmaceuticals Business Overview
8.5.3 eXIthera Pharmaceuticals Venous Thromboembolism Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 eXIthera Pharmaceuticals Venous Thromboembolism Therapeutics Drugs Product Portfolio
8.5.5 eXIthera Pharmaceuticals Recent Developments
8.6 Daiichi Sankyo
8.6.1 Daiichi Sankyo Comapny Information
8.6.2 Daiichi Sankyo Business Overview
8.6.3 Daiichi Sankyo Venous Thromboembolism Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Daiichi Sankyo Venous Thromboembolism Therapeutics Drugs Product Portfolio
8.6.5 Daiichi Sankyo Recent Developments
8.7 Boehringer Ingelheim
8.7.1 Boehringer Ingelheim Comapny Information
8.7.2 Boehringer Ingelheim Business Overview
8.7.3 Boehringer Ingelheim Venous Thromboembolism Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Boehringer Ingelheim Venous Thromboembolism Therapeutics Drugs Product Portfolio
8.7.5 Boehringer Ingelheim Recent Developments
8.8 BMS
8.8.1 BMS Comapny Information
8.8.2 BMS Business Overview
8.8.3 BMS Venous Thromboembolism Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 BMS Venous Thromboembolism Therapeutics Drugs Product Portfolio
8.8.5 BMS Recent Developments
8.9 BioInvent
8.9.1 BioInvent Comapny Information
8.9.2 BioInvent Business Overview
8.9.3 BioInvent Venous Thromboembolism Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 BioInvent Venous Thromboembolism Therapeutics Drugs Product Portfolio
8.9.5 BioInvent Recent Developments
8.10 Aspen Pharma
8.10.1 Aspen Pharma Comapny Information
8.10.2 Aspen Pharma Business Overview
8.10.3 Aspen Pharma Venous Thromboembolism Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Aspen Pharma Venous Thromboembolism Therapeutics Drugs Product Portfolio
8.10.5 Aspen Pharma Recent Developments
8.11 Armetheon
8.11.1 Armetheon Comapny Information
8.11.2 Armetheon Business Overview
8.11.3 Armetheon Venous Thromboembolism Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Armetheon Venous Thromboembolism Therapeutics Drugs Product Portfolio
8.11.5 Armetheon Recent Developments
8.12 Altor Bioscience
8.12.1 Altor Bioscience Comapny Information
8.12.2 Altor Bioscience Business Overview
8.12.3 Altor Bioscience Venous Thromboembolism Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Altor Bioscience Venous Thromboembolism Therapeutics Drugs Product Portfolio
8.12.5 Altor Bioscience Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Venous Thromboembolism Therapeutics Drugs Value Chain Analysis
9.1.1 Venous Thromboembolism Therapeutics Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Venous Thromboembolism Therapeutics Drugs Production Mode & Process
9.2 Venous Thromboembolism Therapeutics Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Venous Thromboembolism Therapeutics Drugs Distributors
9.2.3 Venous Thromboembolism Therapeutics Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.